| Literature DB >> 35755281 |
Jingya Zhao1, Huabei Huang1, Jinyan Zhao1, Xiang Xiong1, Sibo Zheng1, Xiaoqing Wei1, Shaobing Zhou1.
Abstract
Remodeling the tumor microenvironment through reprogramming tumor-associated macrophages (TAMs) and increasing the immunogenicity of tumors via immunogenic cell death (ICD) have been emerging as promising anticancer immunotherapy strategies. However, the heterogeneous distribution of TAMs in tumor tissues and the heterogeneity of the tumor cells make the immune activation challenging. To overcome these dilemmas, a hybrid bacterium with tumor targeting and penetration, TAM polarization, and photothermal conversion capabilities is developed for improving antitumor immunotherapy in vivo. The hybrid bacteria (B.b@QDs) are prepared by loading Ag2S quantum dots (QDs) on the Bifidobacterium bifidum (B.b) through electrostatic interactions. The hybrid bacteria with hypoxia targeting ability can effectively accumulate and penetrate the tumor tissues, enabling the B.b to fully contact with the TAMs and mediate their polarization toward M1 phenotype to reverse the immunosuppressive tumor microenvironment. It also enables to overcome the intratumoral heterogeneity and obtain abundant tumor-associated antigens by coupling tumor penetration of the B.b with photothermal effect of the QDs, resulting in an enhanced immune effect. This strategy that combines B.b-triggered TAM polarization and QD-induced ICD achieved a remarkable inhibition of tumor growth in orthotopic breast cancer.Entities:
Keywords: 4T1 cells, mouse mammary 4T1 tumor cells; AgNO3, silver nitrate; B.b, Bifidobacterium bifidum; B.b@QDs, hybrid bacteria; Bifidobacterium; CRT, calreticulin; CTLs, cytotoxic T lymphocytes; DLS, dynamic light scattering; EC cells, endothelial cells; GC, glycol chitosan; GSH, reduced glutathione; H&E, hematoxylin‒eosin; ICD, immunogenic cell death; Immunogenic cell death; Immunotherapy; Na2S, sodium sulfide; QDs, quantum dots; Quantum dot; TAMs, tumor-associated macrophages; TEM, transmission electron microscopy; TUNEL, transferase-mediated UTP end labeling; Tumor-associated macrophage; XRD, X-ray diffraction
Year: 2021 PMID: 35755281 PMCID: PMC9214064 DOI: 10.1016/j.apsb.2021.10.019
Source DB: PubMed Journal: Acta Pharm Sin B ISSN: 2211-3835 Impact factor: 14.903
Scheme 1(a) Schematic of the preparation of NIR Ag2S QDs. (b) Schematic of the fabrication of the hybrid bacteria B.b@QDs. (c) Schematic of the hybrid bacteria combined with tumor targeting and penetration, tumor-associated macrophage polarization, and photothermal conversion capabilities for improving antitumor immunotherapy in vivo. The QD-hybrid bacteria with hypoxia targeting ability effectively accumulate and penetrate the tumor tissues, enabling them to fully contact with the tumor-associated macrophages and enhance the polarization of M2 macrophages to M1 macrophages. It also enables to overcome the intratumoral heterogeneity and obtain abundant tumor-associated antigens by coupling tumor penetration of the B.b with photothermal effect of the QDs.
Figure 1Characterization of the hybrid bacteria. (a) TEM image of the Ag2S QDs. (b) TEM image of the B.b@QDs, (c) High resolution TEM image of the B.b@QDs and the Ag2S QDs on the B.b@QDs (inset). (d) Elemental mapping images of the Ag2S QDs on the B.b@QDs. (e) Fluorescence images of FITC-labeled B.b after modified with the Ag2S QDs. (f) Flow cytometric histograms of the B.b, B.b@QDs and B.b@QDs-48 h (incubation with DMEM medium for 48 h).
Figure 2In vitro photothermal therapy and ICD induced by the hybrid bacteria. (a) Infrared thermal images of the QDs and B.b@QDs under the irradiation of 808 nm laser (1.0 W/cm2). (b) Temperature curves of the QDs and B.b@QDs under NIR laser irradiation. (c) Fluorescence images showing the cell viability of 4T1 cells treated with different materials. (d) Fluorescence images of CRT expressed on the 4T1 tumor cells after treated by different materials. (e) Flow cytometric histograms and corresponding mean fluorescence intensity of CRT expressed on 4T1 tumor cells after different treatment (n = 3). ∗∗∗P < 0.001.
Figure 3Polarization of macrophages by the hybrid bacteria in vitro. (a) Surface markers of M1 macrophages (CD80+, F4/80+) and M2 macrophages (CD206+, F4/80+) in different groups, detected by flow cytometry. (b) Concentration of TNF-α and IL-6 in the supernatant after co-incubation of macrophages with different materials (n = 3). The cytokine expression level was detected by ELISA. (c) Schematic illustration of a transwell system, which is used to detect immune response in vitro. (d) Cell viability of 4T1 cells in the transwell system after treated with different materials (n = 3). ∗∗∗P < 0.001.
Figure 4Biodistribution and tumor penetration of the hybrid bacteria in vivo. (a) NIR fluorescence images showing the biodistribution of free QDs or B.b@QDs in the body of mice. (b) Gram staining images of tumor tissue sections from the PBS group and the B.b@QDs group. The green arrows point to the bacteria. (c) Fluorescence images of the 4T1 tumors with the maximum sections at 24 h after the injection of QDs or B.b@QDs and corresponding line profiles.
Figure 5Antitumor immunity activation of the hybrid bacteria in vivo. Infrared thermal images (a) of 4T1 tumor-bearing mice intravenously injected with various formulations with or without 808 nm NIR laser irradiation and the corresponding heating curves (b) at the tumor sites in mice. (c) Expression of CRT in tumor tissues of the BALB/c mice after treated with different formulations. (d) Surface markers of M1 macrophages (CD80+, F4/80+) and M2 macrophages (CD206+, F4/80+) from the tumor tissues of the BALB/c mice after treated with different formulations, detected by flow cytometry. (e) Immunohistochemical staining images of IL-6, TNF-α, IL-10 in the tumor tissues from different groups. (f) Immunofluorescence images of the CD8+ and CD4+ T cells in the tumor tissues from different groups.
Figure 6In vivo antitumor effect. Photos of the mice (a) and the excised tumors (b) at the end of treatment on Day 21. Changes of tumor volume (c), tumor inhibition rate (d) and body weight (e) of the mice receiving different treatments (n = 5). (f) H&E and TUNEL staining images of the tumor tissues from the mice at the end of the treatment. ∗∗P < 0.01, ∗∗∗P < 0.001.